Teva signs off $900m Emalex buyout amid strategic pipeline boosting ploy
Teva Pharmaceuticals will acquire neuroscience specialist, Emalex – a move which Teva executive, Evan Lippman, says effectively complements the company’s…
All articles by Annabel Kartal Allen
Annabel Kartal Allen
Annabel Kartal-Allen is a reporter for Clinical Trials Arena, Pharmaceutical Technology and Medical Device Network based in London, UK. Annabel holds interests in oncology, neurology and metabolic diseases. She has previous experience reporting for both the pharmaceutical and nutraceutical industries, and holds a BSc in Biology from the University of Sussex. Contact Annabel
-
-
Eli Lilly bets on recombinases in $2.25bn Profluent R&D pact
Eli Lilly is locking down on its rapid expansion strategy with a second deal this week – joining forces with…
-
Merck KGaA and Remepy join forces to develop combo drug-digital therapies
Merck KGaA has inked a collaboration deal with Israeli-US startup, Remepy, to explore the therapeutic potential of combination drug and…
-
Eli Lilly outlays $2.3bn to acquire blood cancer specialist Ajax Therapeutics
Eli Lilly has added yet another string to its M&A bow of 2026 after agreeing to acquire cancer specialist Ajax…
-
UK biotech could be bound for recovery, BIA report reveals
New data debuted by the UK’s BioIndustry Association (BIA) has hinted towards the recovery of the British biotech financing market,…
-
Regulatory round-up: Novartis, Sanofi and Arrowhead secure CHMP blessings
The European drug market could soon be poised to receive three new entries, as the European Committee for Healthcare and…
-
Regeneron cuts White House pricing deal, offers new gene therapy for free
It’s been a busy few days for Regeneron Pharmaceuticals, which has inked a drug pricing agreement with the White House,…
-
AbbVie opts for North Carolina to house $1.4bn manufacturing site
AbbVie has tapped North Carolina as the location for a new $1.4bn manufacturing site as part of its $100bn US…
-
Medicare weight loss drug pilot on ice as insurers decline to contribute
The Centers for Medicare & Medicaid Services (CMS) has hit pause on its pilot programme designed to offer insurer-fronted access…
-
MSD-backed Ray locks in $125m to back eye drug pipeline
Ray Therapeutics has secured $125m in a Series B funding round, as the gene therapy-focused biopharma eyes a breakout on…